Expertise in
21
conditions

Allan M. Lund

Copenhagen, DK 
Expertise in
21
conditions
Copenhagen, DK 

Overview

Allan Lund practices practicing medicine in Copenhagen, Denmark.

Mr. Lund is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Primary Carnitine Deficiency, Alpha Mannosidosis, Argininosuccinic Aciduria, Urea Cycle Disorders (UCD), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Copenhagen, Denmark
Other Locations
Horsholm, Denmark
Gentofte, Denmark
Hellerup, Denmark
Glostrup, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
Enrollment Status: Completed
Publish Date: July 28, 2023
Intervention Type: Drug
Study Drug: Lamazym
Study Phase: Phase 3
A Multi-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
A Multi-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
Enrollment Status: Completed
Publish Date: July 28, 2023
Intervention Type: Drug
Study Drug: Lamazym
Study Phase: Phase 3
A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Enrollment Status: Completed
Publish Date: June 25, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

144 Total Publications

Disease Outcomes in Boys with ABCD1 Variants Identified by Newborn Screening for X-ALD.
Disease Outcomes in Boys with ABCD1 Variants Identified by Newborn Screening for X-ALD.
Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026

Frequently Asked Questions about Allan M. Lund

Is Allan M. Lund a top-rated expert for Primary Carnitine Deficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Allan M. Lund is classified as an Elite expert for Primary Carnitine Deficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Allan M. Lund participate in research or clinical trials?

Yes. Allan M. Lund has published 144 articles and abstracts on conditions like Primary Carnitine Deficiency. You can view a list of Allan M. Lund's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lund's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 63 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile